Archive

Dive into a collection of past posts and rediscover timeless content.

This Biotech Won the Courtroom Fight and Still Trades Below Its Closest Peers

The company that won a years-long patent war just got a check from the loser. The loser’s stock soared. The winner’s barely moved.

Oct 15, 2026

Undervalued Edge

This Drugmaker’s New Products Now Account for Most of Its Business

The drug company people worry about losing faces generic rivals as early as April 2028. The newer products already make up most of the revenue.

Oct 14, 2026

Undervalued Edge Analysis

A Housing REIT With Sticky Tenants, Rising Rents, and a Valuation Gap to Match

A manufactured housing REIT near its 52-week low just got a Strong Buy upgrade this morning. Earnings are a week out, and the business keeps executing.

Oct 13, 2026

Undervalued Edge

This Frozen Potato Giant Raised Its Outlook and Still Trades Cheap

Restaurant fries come from somewhere, and one of the biggest suppliers just beat, raised guidance, and still pays you over three percent to hold it.

Oct 12, 2026

Undervalued Edge Analysis

One Pill for America’s Biggest Ignored Liver Problem and the Market Is Asleep

The first approved fatty-liver drug just proved it works across major genetic risk groups. Fair-value models peg it more than 40% above where it trades.

Oct 10, 2026

Undervalued Edge

Wall Street Wrote the Wrong Copy on This Advertising Giant’s Future

Everyone is sure AI will gut this industry. Meanwhile, the company is cutting $1.5 billion in costs and paying you over 4% to be patient.

Oct 9, 2026

Undervalued Edge Analysis

The Software Monopoly That Owns Drug Development and Is About to Own AI

A $45B life sciences monopoly raised guidance, won drugmakers, and the AI product that could reprice everything hasn’t touched the P&L yet.

Oct 8, 2026

Undervalued Edge

This Oil Producer More Than Doubled Its Best Acreage With One Four Billion Deal

Four billion dollars changed hands last month and the share price barely blinked. The acreage behind that deal is about to start showing up in the numbers.

Oct 7, 2026

Undervalued Edge Analysis

This Iconic Beverage Company Got Booted From the S&P 500 and Is Now Sitting on Sale

Index funds had to dump it. The business didn’t change. Now it yields over 5%, trades near multi-year lows, and earnings are weeks away.

Oct 6, 2026